BioCentury
ARTICLE | Financial News

BioPorto raises $12.5 million in rights offering

September 7, 2013 12:58 AM UTC

BioPorto Diagnostics A/S (CSE:BIOPOR) raised DKK70.7 million ($12.5 million) through the sale of 70.7 million shares at DKK1 in a rights offering. Existing shareholders were eligible to purchase three shares for every two shares held. BioPorto, which proposed the offering in late May, markets its NGAL Test to diagnose acute kidney injury in Canada and the EU. The in vitro test that detects the lipocalin ( LCN2; NGAL) biomarker produced in the kidneys is also approved in China and Russia and is under review in the U.S. ...